DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1960)

Type 2 Diabetes | Access & Reimbursement | Detailed, Expanded Analysis Type 2 Diabetes A&R (US)

Type 2 Diabetes | Access & Reimbursement | Detailed, Expanded Analysis Type 2 Diabetes A&R (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook

The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition among antidiabetic therapies, the type 2 diabetes access and reimbursement space is both extremely dynamic and highly influential on treatment patterns. Branded therapies experience high rates of prescribing restrictions as payers steer prescriptions toward drugs with lower prices. Manufacturers of agents such as SGLT-2 inhibitors, GLP-1 receptor agonists, and insulins need to skillfully navigate contract agreements/rebates with payers to gain favorable formulary coverage.

Questions answered:

  • On what tiers do payers place leading brands such as Novo Nordisk’s Victoza and Eli Lilly’s Trulicity, and what restrictions do they impose?
  • What clinical factors most influence formulary coverage of type 2 diabetes therapies?
  • What contracting agreements do MCOs report are in place for long-acting insulins such as Sanofi’s Lantus, Novo Nordisk’s Tresiba, and Boehringer Ingelheim/Eli Lilly’s Basaglar?
  • What role does reimbursement, restriction, and patient cost play in physicians’ decisions to prescribe therapies for this indication?
  • What percentage of MCOs use pharmacoeconomic or health economic models such as cost-utility analysis?
  • What is the most compelling type of pharmacoeconomic data in formulary decision-making for type 2 diabetes?

Table of contents

  • Detailed, Expanded Analysis Type 2 Diabetes A&R (US)
    • A & R - 2018 - Type 2 Diabetes (US)

Already a Client? Log in to access this report.

  • Pub Date: July 2018
  • Author(s): Surbhi Gupta, Masters in Pharmacy
  • Surbhi Gupta is an Insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group and has worked on contents on pulmonary hypertension and obesity. She completed her Masters with specialization in Pharmacology, and a Bachelor's degree in Pharmacy from the University Of Delhi. Before joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve, where she was involved in competitive intelligence projects across multiple indications (such as atrial fibrillation, ACS, VTE, renal anemia, and several oncology indications). She also worked as a Medical writer at the clinical research organization, Apcer Pharma.

Purchase Report

Recent reports:
You may also be interested in: